Next Generation Sequencing (NGS) is a high-throughput DNA sequencing technology that separates billions or millions of DNA strands and sequence in parallel, yielding more output and reducing the need for fragment-cloning methods (Sanger sequencing of genomes). However, read lengths for NGS are shorter than Sanger due to the signal to noise ratio, which increases with read length. NGS allows simultaneous screening of mutations in large number of genes. For example, a patient with symptoms of Leigh syndrome can perform exome sequencing to find candidate gene variants. Furthermore, it is used for analysis and for interpreting sequenced data, analyzing specific gene associated with the patient’s clinical condition
The global next generation sequencing market is estimated to be valued at US$ 12,870.5 million in 2022 and is expected to exhibit a CAGR of 18.3% during the forecast period (2022-2030).
Figure 1.Global Next Generation Sequencing Market Share (%), by Application, 2022
Rising demand for early detection of cancer and infectious diseases are expected to drive growth of the next generation sequencing market
The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases such as tuberculosis, meningococcal disease, etc. For instance, according to the data provided by World Health Organization (WHO) in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
|Base Year:||2021||Market Size in 2022:||US$ 12,870.5 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||18.3%||2030 Value Projection:||US$ 49,279.9 Mn|
Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian
|Restraints & Challenges:||
Figure 2.Global Next Generation Sequencing Market Share (%), by Region, 2022
Increasing advancements in next generation sequencing procedures are expected to drive the market growth during the forecast period.
Demand for DNA testing is increasing, due to advancements in next generation sequencing instruments and technologies, faster results and cost effectives of the process as compared to genotyping based DNA microarray. For instance, in January 2022, a new ultra-rapid genome sequencing approach developed by Stanford Medicine scientists and their collaborators was used to diagnose rare genetic diseases in an average of eight hours. Genome sequencing allows scientists to see a patient’s complete DNA makeup, which contains information about everything from eye color to inherited diseases. Genome sequencing is vital for diagnosing patients with diseases rooted in their DNA
Global Next Generation Sequencing– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, vaccines and medical devices, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another
However, the COVID-19 pandemic had a positive impact on the global next generation sequencing market, owing to the increased research and development activities by the key players for utilizing next generation sequencing techniques for the diagnosis of COVID-19 infections. For instance, in June 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Illumina, Inc., a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis, for the first COVID-19 diagnostic test utilizing next generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider
Global Next Generation Sequencing: Key Developments
In June 6, 2022, PerkinElmer, Inc., a global corporation focused in the business areas of diagnostics, life science research, food, environmental and industrial testing, announced the launch of the research use only (RUO) BioQule NGS System , an automated benchtop solution for next-generation sequencing (NGS) library preparation of up to eight samples. By incorporating automated thermocycling, integrated quality control through optical quantification and robust liquid handling technology into a single device, the BioQule NGS System enables researchers to produce high quality NGS libraries that yield reliable, reproducible results in a variety of applications requiring genomic analysis
In May, 2022, NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced a seamless, cloud-based workflow that improves the spatial data analysis experience of customers using Illumina NextSeq 1000 and NextSeq 2000 sequencing systems and the GeoMx Digital Spatial Profiler. The spatial analysis of whole transcriptomes combined with proteome analytes can now be simplified using this integrated, push-button run planning tool.
Global Next Generation Sequencing: Restraint
The major factors that hinder growth of the global next generation sequencing market include the storage and management issue of enormous data generated by next generation sequencing and its interpretation. Nevertheless, in spite of tremendous advancements to broaden NGS applications from research to clinic, NGS still presents enormous challenges in terms of data storage, processing, quality control management and interpretation, which slow the translation from the bench-top to the bed-side
Major players operating in the global next generation sequencing market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian
Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.
NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.
The increasing adoption of inorganic strategies such as agreements and partnerships among the key players in the market to advance comprehensive genomic profiling using next generation sequencing is expected to drive the market growth over the forecast period. For instance, in January 2021, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a strategic collaboration with Illumina, Inc., a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis, for Illumina to create a kit-based version of the myChoice companion diagnostic (CDx) test for international markets. The agreement between Myriad Genetics, Inc., and Illumina, Inc., combines companion diagnostics and next-generation sequencing to advance comprehensive genomic profiling of tumor samples and drive improved outcomes in oncology
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients